Director Christopher Gibson executed a sale of 40,000 shares of Recursion Pharmaceuticals Class A common stock on March 23, 2026, at a price of $3.25 per share, yielding total proceeds of $130,000. The transaction occurred as the stock traded near its 52-week low of $2.98 and after a year in which shares fell approximately 51%.
On the same calendar day, Gibson also completed a conversion of 40,000 shares of Class B common stock into Class A common stock. That conversion carried a price of $0 and a total value of $0.
Following the sale and conversion, Gibson directly holds 906,556 shares of Recursion Pharmaceuticals Class A common stock. He continues to have indirect Class B holdings through related entities: 386,000 shares of Class B common stock are held via LAHWRAN-3 LLC, 388,000 shares of Class B common stock are held via LAHWRAN-4 LLC, and 50,000 shares of Class B common stock are held by the Gibson Family Trust.
Company results and leadership update
Recursion’s fourth-quarter 2025 financials outperformed analyst projections. The company reported an earnings per share of negative $0.21, better than the forecasted negative $0.30. Revenue for the quarter was $35.54 million, a figure that exceeded expectations by 45%.
In addition to the quarterly results, Recursion disclosed a leadership transition in its medical group. Vicki Goodman, M.D., is slated to assume the role of Chief Medical Officer effective April 6, 2026, taking over from David Mauro, M.D., Ph.D. The company noted that Dr. Goodman brings more than two decades of experience in oncology drug development and medical leadership.
Analyst commentary and valuation notes
BofA Securities adjusted its price target for Recursion Pharmaceuticals from $7.00 to $6.00 while retaining a Neutral rating. The firm emphasized the need for repeatable clinical successes to validate the effectiveness of Recursion’s AI-derived biology. BofA also observed that the FAP data for REC-4881 looks promising, but indicated that most clinical value is expected to materialize in 2027.
Separately, InvestingPro analysis mentioned that the stock appears undervalued at current levels, trading below Fair Value. The platform indicates that subscribers can access nine additional ProTips and more comprehensive analysis via its Most Undervalued Stocks list.
Context for investors
The insider sale and simultaneous conversion of Class B shares to Class A shares alter the composition of Gibson’s direct and indirect holdings without introducing new capital into the converted shares. The company’s recent quarterly beat and the appointment of an experienced CMO are notable corporate developments that accompany the market valuation and analyst commentary described above.